Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models

• Published in: Investigational new drugs 2023-10, Vol.41 (5), p.699-709
• Main Authors: Lam, Rachel C.T., Hui, Connie W.C., Wong, C. H., Lo, K. W., Tsang, Anna C.M., Hui, Edwin P., Chan, Anthony T.C., Ma, Brigette B.Y.
• Format: Article
• Language: English
• Subjects: Angiogenesis; Angiopoietin; Antiangiogenics; Anticancer properties; Antiproliferatives; Bevacizumab; Endothelial cells; Epstein-Barr virus; Growth factors; Hypoxia; Hypoxia-inducible factors; Immunomodulation; Macrophages; Medicine; Medicine & Public Health; Metastases; Microenvironments; Monoclonal antibodies; Nanobodies; Nasopharyngeal carcinoma; Necrosis; Oncology; Patients; Pharmacology/Toxicology; Throat cancer; Tumors; Vascular endothelial growth factor; Xenotransplantation
• ISSN: 0167-6997; 1573-0646
• DOI: 10.1007/s10637-023-01384-1

Summary Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) is endemic to parts of Asia and overexpression of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1α are common in NPC. Anti-vascular agents have known clinical activity in patients with recurrent/ metastatic NPC and in this study, we investigated the anti-tumor effect of BI 836880, a humanized bispecific nanobody against VEGF and angiopoietin-2 (Ang2), in preclinical models of EBV-positive and EBV-negative NPC. The efficacy of BI 836880 was also compared with bevacizumab, a recombinant humanized monoclonal antibody against VEGF. We found that BI 836880 could exert growth-inhibitory effect on endothelial cells (HUVEC-C) and the EBV-negative NPC cell line (HK1), but to a lesser extent in the EBV-positive NPC cell lines, C17C and C666-1. In patients-derived xenograft (PDX) models of NPC - Xeno-2117 and Xeno-666, BI 836880 could suppress tumor growth and Ki67, as well as induce tumor necrosis and reduce microvessel density. Moreover, treatment with BI 836880 increased the level of macrophage infiltration in both PDX tumor models of NPC, suggesting that BI 836880 may exert immunomodulatory effect on the NPC immune microenvironment. When compared with bevacizumab, BI 836880 appeared to show at least comparable activity as bevacizumab in terms of its anti-proliferative and anti-angiogenic effects. This study showed that BI 836880 has anti-proliferative, anti-angiogenic and possibly immunomodulatory effect in clinical models of NPC, therefore the dual targeting of VEGF and Ang2 signaling in NPC should be further investigated.